Van Lanschot Kempen Investment Management N.V. Has $60.15 Million Stock Position in Envista Holdings Co. (NYSE:NVST)

Van Lanschot Kempen Investment Management N.V. reduced its position in Envista Holdings Co. (NYSE:NVST - Free Report) by 2.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 3,118,123 shares of the company's stock after selling 72,966 shares during the period. Van Lanschot Kempen Investment Management N.V. owned about 1.81% of Envista worth $60,149,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Venturi Wealth Management LLC raised its position in shares of Envista by 528.4% in the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock valued at $38,000 after purchasing an additional 1,638 shares during the period. GAMMA Investing LLC raised its holdings in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock valued at $44,000 after acquiring an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Envista during the fourth quarter worth approximately $53,000. Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of Envista during the fourth quarter worth approximately $86,000. Finally, KBC Group NV grew its position in shares of Envista by 63.9% in the fourth quarter. KBC Group NV now owns 7,903 shares of the company's stock valued at $152,000 after purchasing an additional 3,082 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have commented on NVST shares. New Street Research set a $19.00 price objective on Envista in a report on Thursday, March 6th. UBS Group lowered their price target on shares of Envista from $23.00 to $21.00 and set a "neutral" rating on the stock in a research report on Monday, March 10th. Needham & Company LLC reissued a "hold" rating on shares of Envista in a report on Thursday, March 6th. Jefferies Financial Group raised their target price on shares of Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a report on Thursday, January 23rd. Finally, JPMorgan Chase & Co. cut their price target on Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $19.96.

Envista Price Performance

Shares of Envista stock traded down $0.02 during midday trading on Friday, hitting $15.96. 2,273,467 shares of the company traded hands, compared to its average volume of 2,777,352. The firm's fifty day moving average price is $17.34 and its 200-day moving average price is $19.12. The stock has a market cap of $2.75 billion, a price-to-earnings ratio of -2.46, a PEG ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a 12 month low of $14.22 and a 12 month high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, sell-side analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.